Regulatory Toxicology and Pharmacology retracted a highly cited paper that had concluded glyphosate posed no cancer risk, citing reliance on unpublished Monsanto studies, possible ghostwriting, and undisclosed financial ties. The retraction removes a widely cited piece of evidence used by regulators and raises questions about prior risk assessments. The move coincides with a U.S. administration brief supporting Bayer's bid to overturn thousands of glyphosate lawsuits at the Supreme Court. Scientists and public‑health advocates are calling for regulatory agencies, including the EPA, to reexamine prior conclusions that relied on the now‑retracted paper.